drugset
drugset / Trial / NCT03586570

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

NCT03586570 ↗

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd. Janssen Biotech, Inc. · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.

Timeline

Start
2018-07-17
Primary completion
2018-09-10
Completion
2018-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprocitentan Small molecule 25 mg Oral

Indications

No indication recorded.